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Abstract
The phosphatidylinositol 3-kinase (PI3K) pathway is a central mediator of vascular endothelial growth factor
(VEGF)–driven angiogenesis. The discovery of small molecule inhibitors that selectively target PI3K or PI3K and
mammalian target of rapamycin (mTOR) provides an opportunity to pharmacologically determine the contribu-
tion of these key signaling nodes in VEGF-A–driven tumor angiogenesis in vivo. This study used an array of micro-
vascular imaging techniques to monitor the antivascular effects of selective class I PI3K, mTOR, or dual PI3K/
mTOR inhibitors in colorectal and prostate cancer xenograft models. Micro-computed tomography (micro-CT) angio-
graphy, dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI), vessel size index (VSI) MRI, and DCE
ultrasound (DCE-U/S) were employed to quantitatively evaluate the vascular (structural and physiological) response
to these inhibitors. GDC-0980, a dual PI3K/mTOR inhibitor, was found to reduce micro-CT angiography vascular
density, while VSI MRI demonstrated a significant reduction in vessel density and an increase in mean vessel
size, consistent with a loss of small functional vessels and a substantial antivascular response. DCE-MRI showed
that GDC-0980 produces a strong functional response by decreasing the vascular permeability/perfusion-related
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mammalian target of rapamycin; micro-CT, micro-computed tomography; PI3K, phosphatidylinositol 3-kinase; VEGF-A, vascular endothelial growth factor A; VSI, vessel size
index; S6RP, S6 ribosomal protein
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parameter, K trans. Interestingly, comparable antivascular effects were observed for both GDC-980 and GNE-490
(a selective class I PI3K inhibitor). In addition, mTOR-selective inhibitors did not affect vascular density, sug-
gesting that PI3K inhibition is sufficient to generate structural changes, characteristic of a robust antivascu-
lar response. This study supports the use of noninvasive microvascular imaging techniques (DCE-MRI, VSI
MRI, DCE-U/S) as pharmacodynamic assays to quantitatively measure the activity of PI3K and dual PI3K/mTOR
inhibitors in vivo.
Neoplasia (2013) 15, 694–711
Introduction
Angiogenesis is a hallmark of cancer where activation of proangio-
genic factors predominates over antiangiogenic factors resulting in
tumor vasculature growth [1]. Of these proangiogenic factors, vas-
cular endothelial growth factor A (VEGF-A) has been identified as
a central mediator of angiogenesis, promoting endothelial cell pro-
liferation, survival, migration, and increased vascular permeability
[2–5]. The approval of therapies that target VEGF-A or its receptors
for the treatment of several types of solid tumors has provided clinical
proof of concept that angiogenesis is an integral component of tumor
cell growth and metastasis [6–8].
VEGF ligands bind to and activate three structurally similar type I
receptor tyrosine kinases: VEGFR1/FLT1, VEGFR2/KDR, and
VEGFR3/FLT4 [9,10]. VEGFR2 expression is restricted primarily
to the vasculature and, upon ligand binding, mediates signal trans-
duction primarily through the phosphatidylinositol 3-kinase (PI3K)
pathway. The rate-limiting enzyme of this pathway is the lipid kinase,
PI3K, and consists of enzymatic subunits that are subdivided, on the
basis of sequence homology and substrate specificity, into class I, II,
and III and the p85/p55 regulatory subunits [11]. The class I sub-
group consists of p110α, p110β, p110δ, and p110γ isoforms that
generate phosphatidylinositol 3,4,5-trisphosphate from phosphatidyl-
inositol 4,5-bisphosphate, resulting in membrane anchorage of the
effector kinases, Akt, and downstream activation of the mammalian
target of rapamycin (mTOR) C1/C2 complexes [11]. Activating and
transforming mutations in the PIK3CA gene of the p110α subunit of
PI3K are commonly found in breast, colorectal, endometrial, and
ovarian cancers [11–13]. Thus, there is a strong rationale for targeting
PI3K in the context of both tumorigenesis and angiogenesis.
While PI3K inhibitors such as LY294002 and wortmannin have
demonstrated antiangiogenic properties [14–17], the lack of selectivity
and poor pharmaceutical properties of these drugs precludes assessment
of the specific contribution of PI3K in regulating VEGF-mediated
tumor angiogenesis in vivo. Moreover, the role of PI3K in angiogenesis
has been primarily defined by using morphologic and histologic criteria
during development [18]. The effects of a dual PI3K/mTOR selective
inhibitor (BEZ-235) on tumor vascular physiology has been evaluated
in a BN472 mammary carcinoma allograft model in which drug treat-
ment altered physiological parameters associated with the tumor micro-
vasculature leakage [19]. While this study also demonstrated decreased
vascularization in normal tissue after BEZ-235 treatment, it did not
address the direct effects of dual PI3K/mTOR inhibition on tumor
vascular structure. The latter point is important because suppression
of tumor vascular growth and decreased tumor vascularization are
key structural changes consistent with effective antiangiogenic therapies
[20–22]. Thus, collectively, the precise structural and functional
consequences of selectively inhibiting the PI3K pathway on tumor
angiogenesis have not been thoroughly documented. The advent of
PI3K-selective small molecule inhibitors, as well as those that have dual
PI3K and mTOR antagonistic activity, provides a unique opportunity
to pharmacologically dissect the specific contribution of these key
signaling nodes in VEGF-A–driven tumor angiogenesis. Moreover,
the development of multiparametric imaging techniques enables inves-
tigators to quantitatively assess the activity of antiangiogenic drugs non-
invasively in vivo using both structural and physiological end points
[22–25].
In this study, an array of complimentary imaging techniques were
employed to characterize the structural and functional changes induced
in the tumor vasculature after treatment with class I PI3K (GNE-490
[26]), mTOR (rapamycin and GNE-861 [27]), and dual PI3K/mTOR
(GDC-0980 [28–30]) inhibitors in highly vascularized colorectal
(HM-7) cancer xenograft model that is sensitive to an anti–VEGF-A
therapy [31]. In addition, a second, less vascularized, prostate (NCI-
PC3) cancer xenograft model was also evaluated. The techniques
include micro-computed tomography (micro-CT) angiography and
vessel size index magnetic resonance imaging (VSI MRI) to assess
vascular structure and dynamic contrast-enhanced MRI (DCE-MRI)
and DCE ultrasound (DCE-U/S) to provide both functional and struc-
tural assessments of the tumor vasculature. Micro-CT angiography is an
ex vivo technique that provides high-resolution three-dimensional (3D)
images to assess tumor vascular structure as a means to quantify vascular
density [22,24]. VSI MRI combined with ultrasmall superpara-
magnetic iron oxide (USPIO) nanoparticles provides robust measures
of tumor microvascular structure [25,32,33]. The long half-life and
minimal leakage of USPIOs increase the available time for imaging,
yielding high signal-to-noise images to produce quantitative estimates
of mean vessel size, blood volume (BV), and a vessel density–related
parameter, Q [25,32,33]. DCE-MRI employs rapid imaging to assess
the pharmacokinetics of a small molecule Gd-based contrast agent as
the agent moves between the tumor vasculature and the interstitial
space [34]. The time-series imaging data are fitted to a kinetic model
that provides quantitative parameters associated with fractional plasma
volume (vp), extravascular extracellular leakage space (ve), and the leak-
age rate, K trans, a parameter sensitive to changes in both blood flow and
permeability [23,34,35]. DCE-U/S imaging employs microbubble
contrast agents to assess blood flow [36]. The microbubble contrast
agents remain intravascular because of their size (1 to 3 μm) removing
the need to account for leakage in blood flow estimates [36]. The focus
of this study was to employ these pharmacological agents and tech-
niques to address the following questions: 1) Does dual PI3K/mTOR
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inhibition produce a strong and rapid antivascular (structural) response
in tumors similar to other molecules (anti–VEGF-A) that interfere with
VEGF’s actions? 2) Is PI3K inhibition alone sufficient to generate this
antivascular effect?
Given that potent and selective PI3K and dual PI3K/mTOR
inhibitors have entered clinical development for the treatment of
cancer [37], an additional goal of our study was to assess the utility
of microvascular imaging end points as biomarkers to measure response
to drug treatment in vivo. Assays currently employed in the clinic to
measure the activity of PI3K pathway inhibitors in tumors assess
change of pathway biomarkers in tumor biopsy sections by immuno-
histochemistry (IHC) or, recently, by suppression of glucose uptake
in vivo by [18F]-fluorodeoxyglucose positron emission tomography
(FDG-PET) imaging [38]. However, both methodologies have limita-
tions: 1) tumor biopsy collection is invasive and immunohistochemical
evaluation is semiquantitative and 2) interpretation of FDG-PET results
are confounded by hyperglycemia that is commonly associated with
PI3K inhibitor treatment [39]. Given the essential role of PI3K in
VEGF-mediated signal transduction during tumor angiogenesis, our
aim was to determine the utility of the microvascular imaging tech-
niques described above as pharmacodynamic assays to measure the
activity of PI3K, mTOR, and dual PI3K/mTOR inhibitors in vivo.
Our preclinical data demonstrate that dual PI3K/mTOR inhibi-
tion produces a rapid and robust antivascular response, altering both
tumor vascular structure and function. Interestingly, PI3K inhibition
by GNE-490 generated similar antivascular responses (structural and
physiological) to GDC-0980 suggesting that PI3K pathway inhibi-
tion at the level of PI3K itself is sufficient to generate antiangiogenic
effects. In addition, our work demonstrates the utility of advanced
noninvasive microvascular imaging techniques (DCE-MRI, VSI
MRI, and DCE-U/S) to assess the pharmacodynamic activity of
PI3K and dual PI3K/mTOR inhibitors in vivo.
Materials and Methods
Cell Lines and Inhibitors
HM-7 colorectal cancer cells were purchased from ATCC
(Rockville, MD), and NCI-PC3 prostate cancer cells were obtained
through a material transfer agreement between Genentech (South
San Francisco, CA) and the National Cancer Institute (Fredrick,
MD). Tumor cell lines were grown in RPMI 1640 media supplemen-
ted with 10% FBS, L-glutamine, and penicillin/streptomycin (Sigma-
Aldrich, St Louis, MO) before implantation in immunocompromised
mice. Human umbilical vein endothelial cells (HUVECs) were cultured
in EGM-2 containing growth factor media (Lonza, Allendale, NJ).
B20.4.1.1, GDC-0980, and GNE-490 were generated at Genentech.
Western Blot Analysis
HUVECs were starved for 16 hours before stimulation with EGM-2
containing growth factor media (Lonza) for 1 hour with DMSO
(vehicle), 0.40 μM GNE-490, or 0.40 μM GDC-0980. Following
treatment, cells were lysed and equal amounts of protein were sepa-
rated by electrophoresis, transferred onto polyvinylidene difluoride
(PVDF) membranes, and probed with monospecific primary anti-
bodies (Cell Signaling Technology, Beverly, MA) to phosphorylated
Akt (pAkt; S473 and T308), total Akt (tAkt), phosphorylated S6 ribo-
somal protein (pS6RP; S235/236), total S6RP (tS6RP), phosphorylated
4EBP (T37/46), total 4EBP, phosphorylated eNOS, total eNOS, and
β-actin. Primary binding was detected with LI-COR’s IRDye 680 or
IRDye 800 infrared secondary antibodies using the LI-COR Odyssey
Imaging System.
Endothelial Cell Migration and Sprouting Assays
Real-time monitoring of endothelial cell migration was performed
using the xCELLigence System and CIM-Plate 16 (Roche, Pleasan-
ton, CA). The upper chamber was coated with 20 μg/ml fibronectin
and seeded with 50,000 HUVECs in EBM-2 basal media followed
by stimulation with EGM-2 endothelial growth factors in the pres-
ence or absence of 0.40 μM GNE-490 or 0.40 μM GDC-0980.
Cells migrating into the bottom chamber in response to attractants
contacted and adhered to the electronic sensors, resulting in an
increase in impedance. The cell migration index values reflecting
impedance changes were automatically recorded every 15 minutes.
Angiogenic sprouting assays were performed using 20 μg/ml anti-
ragweed IgG (control), 20 μg/ml bevacizumab (anti–VEGF-A),
0.40 μM GNE-490, or 0.40 μM GDC-0980 as previously de-
scribed [40] but with conditioned media from fibroblasts. Cells
were imaged using Molecular Devices (Sunnyvale, CA) ImageXpress
Micro automated microscope with a 4× S Fluor objective and quanti-
fied with a modified neurite detection script (MetaXpress software;
Molecular Devices).
Nuclear ELISA Apoptosis Assay
HUVECs were cultured in 96-well plates (5000 cells/well) in the
presence of EGM-2 growth factor containing media and treated with
0.40 μM GNE-490, 0.40 μM GDC-0980, or DMSO vehicle for
48 hours. Cells were stained with Alamar blue for 2 hours before lysis,
and apoptosis was determined (on the basis of the presence of cyto-
plasmic histone-associated DNA fragments) using the Cell Death
Detection ELISAplus Kit (Roche Applied Science, Indianapolis, IN).
Animal Models for In Vivo Efficacy and Imaging
All in vivo studies were approved by Genentech’s Institutional
Animal Care andUse Committee and adhere to theNational Institutes
of Health Guidelines for the Care and Use of Laboratory Animals.
Human tumor xenografts for in vivo efficacy and imaging studies were
established by subcutaneous injection of 3.5 × 106 HM-7 cells/nude
mouse (Harlan Laboratories, Livermore, CA) or 5 × 106 NCI-PC3
cells/nude mouse (Charles River Laboratories, Hollister, CA). Animals
were distributed into treatment groups when tumors reached a mean
volume of approximately 150 to 250 mm3. B20.4.1.1 (10 mg/kg) and
rapamycin (6 mg/kg) were administered intraperitoneally (i.p.) in
saline, while GDC-0980 (7.5 or 10 mg/kg), GNE-490 (30 mg/kg), and
GNE-861 (100 mg/kg) were administered by oral gavage (p.o.) in
0.5%methycellulose/0.2%Tween 80 (MCT) vehicle over a treatment
period spanning 7 days. For efficacy studies, drugs were administered
at tolerated doses (based on <15% body weight loss) to tumor-bearing
mice (n = 8–10/group) daily for 7 days. Body weights and tumor
volumes [caliper-based ellipsoid model: L × W 2/2, where the larger (L)
and smaller (W ) perpendicular dimensions are measured] were recorded
twice weekly. Percent tumor growth inhibition (TGI) was calculated at
the end of drug treatment on day 7 using the following formula:%TGI =
100 × (mean tumor volume in the vehicle-treated group at day 7 −mean
tumor volume of drug-treated group at day 7/mean tumor volume of
vehicle-treated group at day 7).
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VEGF-A ELISA Assays
HM-7 tumor–bearing mice (n = 4/group) were treated with a
single oral dose of MCT vehicle, GNE-490 (30 mg/kg), or GDC-
0980 (10 mg/kg). Tumors from each group were harvested 1, 4, 8,
and 24 hours post-dose, immediately frozen in liquid nitrogen, and
homogenized for analysis of VEGF-A isoforms 121 and 165 as previ-
ously described [41].
PI3K Pathway Biomarker Assays
HM-7 or NCI-PC3 tumor xenograft fragments (n = 3–4/group)
were collected following a single dose of drug or after 7 continuous daily
doses. Tumors were dissected and immediately frozen in liquid nitro-
gen for biochemical analysis or fixed in 10% neutral buffered formalin
for 24 hours and embedded in paraffin for IHC. Meso Scale Discovery
(Rockville, MD) assays were performed as per the manufacturer’s in-
structions for pAktS473, tAkt, pS6RPS235/236, and tS6RP using 2 mg/ml
protein lysates per well. Each sample was run in duplicate, analyzed
on a SECTOR Imager 6000, and reported as a ratio of phosphorylated
protein to total protein ± SEM.
Immunohistochemistry
Mouse endothelium marker, MECA-32, was evaluated using 5-μm
paraffin sections of formalin-fixed tumor tissue, treatment with antigen
retrieval buffer (VMSI, Oro Valley, AZ), and incubation with anti–
MECA-32 (Cell Signaling Technology, Danvers, MA) at 37°C. Bound
antibody was detected using DABMap technology (VMSI) and sections
were counterstained with hematoxylin. Images were acquired by the
Olympus (Center Valley, PA) Nanozoomer automated slide scanning
platform (Hamamatsu, Hamamatsu City, Japan) at ×200 final mag-
nification and analyzed in the Matlab software package (Mathworks,
Natick, MA). Viable tumor regions were identified on the basis of
the size, shape, and density of hematoxylin staining of individual viable
tumor cells. The brown MECA-32 staining was isolated using a sup-
port vector machine trained to perform morphologic segmentation of
individual vessels. The vascular fraction (%) = 100 × vascular area/
viable tumor area was calculated.
Micro-CT Angiography
Micro-CT angiography studies were performed 24 hours (HM-7
model; n = 8–10/group) or 48 hours (NCI-PC3 model; n = 8–10/
group) after a single dose of MCT (vehicle control) or drug at the doses
and routes described above. Upon sacrifice, mice were perfused with
lead chromate latex (MICROFIL; Flowtech, Carver, MA) under a state
of pharmacologic vasodilation by sodium nitroprusside as previously
described [24]. Ex vivo tumors were imaged on a SCANCO Medical
(Brüttisellen, Switzerland) Micro-CT 40 System (45 kV, 177 μA,
450 milliseconds, and 16-μm isotropic voxels). The vascular network
and tumor volume were automatically extracted from the images [24].
Vascular density was defined as the ratio of vascular volume to tumor
volume [22,24].
Multispectral VSI MRI
Multispectral VSI MRI was performed pre-treatment and 24 hours
post-treatment with 10 mg/kg GDC-0980 (n = 9) or vehicle control
(n = 9) in HM-7 tumor xenografts on a 4.7-T Agilent (Santa Clara,
CA) Unity Inova MRI System with an Agilent 20-mm two-loop
surface coil. Eight coronal, 1-mm-thick slices were acquired with a
25.6 × 25.6 mm field-of-view (FOV) and 64 × 64 (diffusion and
T2 sequences) or 128 × 128 (T2* sequence) matrix. A diffusion-
weighted fast spin-echo multislice imaging sequence was used to ob-
tain apparent diffusion coefficient (ADC) measurements: six b values
(82–1129 s/mm2), repetition time (TR) = 3 seconds, echo train
length = 4, number of excitations (NEX) = 2, diffusion gradient
length = 3.3 milliseconds, and diffusion gradient separation = 30milli-
seconds. T2 and M0 maps were generated using a multiecho, multi-
slice spin-echo imaging sequence [echo time (TE) = 5, 26, 47,
68 milliseconds, TR = 3 seconds, and NEX = 1]. T2* maps were gen-
erated using a multiecho, multislice gradient echo sequence (TE = 5,
10, 15, 20, 25, 30, 35, 40 milliseconds, TR = 345 milliseconds, and
NEX = 4). Subsequently, a USPIO contrast agent (200 μmol/kg,
Molday ION; BioPAL Inc, Worcester, MA) was delivered through
tail vein catheter, and post-contrast multiecho, multislice and multi-
echo, multislice gradient echo sequences were repeated to calculate T2
and T2* maps, respectively. Multispectral VSI MRI parameters (vessel
density–related Q, VSI, and fractional BV) were calculated voxel by
voxel in the viable tumor using a multispectral approach. The multi-
spectral approach was similar to that described in Ungersma et al. [25]
but differed in that only ADC and proton density features were em-
ployed in the K-means clustering and the tumor was classified into
three classes (viable tumor, necrosis, and subcutaneous fat). Viable
tumor volume and percent necrosis (ratio of the volume of necrosis class
to the sum of the volumes of the viable and necrosis classes) estimates
were calculated from the classification. Negative ΔR2 or ΔR2* values
were assumed to result from poor perfusion; in these cases, Q and/or
BV were set to zero and included in the mean estimates. However, only
nonzero and positive values were assumed to be valid and were included
in the VSI estimates.
Multispectral DCE-MRI
Multispectral DCE-MRI studies were performed in HM-7 tumor
xenografts to compare 1) GDC-0980 (7.5 mg/kg, n = 9) and vehicle
control (n = 11) pre-treatment, 4 and 24 hours post-treatment and 2)
GDC-0980 (10 mg/kg, n = 13), GNE-490 (30 mg/kg, n = 11), and
vehicle control (n = 14) pre-treatment and 24 hours post-treatment.
MRI was performed with an Agilent 9.4-T MRI System employing
an Agilent volume transmit (63 mm)/surface receive (20 mm) coil
setup. Twelve coronal, 1-mm-thick slices were acquired with a
25.6 × 25.6 mm FOV and 64 × 64 matrix for ADC and T2 map-
ping. ADC, T2, and M0 maps were acquired as described for VSI
MRI with the exception of TR = 3.7 seconds for the diffusion-
weighted fast spin-echo multislice imaging sequence. In both studies,
pre-contrast 3D gradient echo data sets were acquired at 2° and 10° flip
angles, TR = 6 milliseconds, and NEX = 4. The first study used TE =
1.81 milliseconds, FOV = 51.2 × 25.6 × 32 mm, and a 128 × 64 ×
32 matrix, while the second study used TE = 1.26 milliseconds,
FOV = 25.6 × 25.6 × 16mm, and a 64 × 64 × 16matrix. Gadodiamide
(Omniscan; GE Healthcare, Little Chalfont, United Kingdom) at
1 mmol/kg in 100 μl was injected through a tail vein catheter following
collection of the pre-contrast images. Post-contrast 3D gradient echo
images were then acquired for 30 minutes using a 10° flip angle, TR =
6 milliseconds, NEX = 1, and TE = 1.81 milliseconds (first study) or
1.26 milliseconds (second study) approximately every 15 seconds (first
study) or 9 seconds (second study). The DCE-MRI analysis of K trans,
vp, and ve was restricted to the viable tumor using a multispectral
approach [23]. The volume of viable tumor and percent necrosis are
estimated as previously described [42].
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DCE-U/S Microbubble Reflow Kinetics
DCE-U/S studies were performed pre-treatment and 24 hours
post-treatment in HM-7 tumor xenografts to compare 1) GDC-
0980 (7.5 mg/kg, n = 6) and MCT (vehicle control, n = 6) and 2)
GDC-0980 (10 mg/kg, n = 8), GNE-490 (30 mg/kg, n = 7), and
MCT (vehicle control, n = 8). A Siemens Acuson Sequoia C512
System (Siemens Medical Solutions USA, Malvern, PA) equipped
with a 15L8-S linear transducer was used for harmonic ultrasound
imaging: frequency = 14 MHz, transmitted power = −10 dB/0.21
mechanical index, and 20 frames/s. A vascular microbubble contrast
agent (DEFINITY; Lantheus Medical Imaging, North Billerica, MA)
was delivered through a jugular vein catheter at a constant of 3 μl/min
using a syringe pump. Following bubble destruction from a high-
intensity pulse, reflow kinetics was fitted to a kinetic model [36].
Enhancement factor was defined as the percentage of voxels within
the tumor area where the voxel’s mean pre-contrast signal intensity
was two SDs below the mean of the last 10 temporal samples.
Flow-mediated Dilation Reactive Hyperemia by Ultrasound
Flow-mediated dilation (FMD) reactive hyperemia studies were
performed in C57/BL6 immunocompetent mice (Charles River
Laboratories). Vascular function was determined by ultrasound exam-
ination of the femoral artery (FA) to FMD and nitroglycerin (NTG)
dilatation. A study was performed to compare GDC-0980 (10 mg/kg,
n = 9), GNE-490 (30mg/kg, n = 9), and vehicle control (n = 9) 4 hours
post-treatment. Hair from the ventral surface of the hind limbs was
removed using Nair (Church & Dwight Co, Princeton, NJ) to enable
b-mode imaging using the VisualSonics (Toronto, CN) Vevo770 with
a 55-MHz imaging probe. For FMD, a baseline image of the FA was
collected and a rubber band was subsequently used as a temporary
tourniquet to occlude FA blood flow for 4 minutes. The rubber band
was then released for reflow of the FA and an image was acquired every
minute for 4 minutes and analyzed to estimate FAmaximum diameter
using manufacturer-supplied software tools. For NTG, a baseline image
of the FA was collected, an i.p. injection of 20 μg of NTG was admin-
istered, and images were acquired every minute for 4 minutes and ana-
lyzed for FA maximum diameter.
Statistical Analysis
Statistical significance was defined as P < .05. To compare two
groups, an unpaired t test assuming unequal variances was used;
for three or more groups, a comparison with control using Dunnett’s
method was used. To compare pre-treatment to post-treatment data
within a group, a matched paired t test was used. All summary statis-
tics of the results are given as means ± SEM.
Results
Dual PI3K/mTOR Inhibition Induces Antivascular Effects
and Results in Significant Loss of Functional Vessels
To determine the vascular response when both PI3K and mTOR
are simultaneously blocked, the effects of a dual PI3K/mTORC1/C2
inhibitor, GDC-0980, on tumor vascular structure was initially eval-
uated in the HM-7 human colorectal cancer xenograft model since
it is highly vascularized and sensitive to antiangiogenic agents such as
a neutralizing antibody to rodent and human VEGF-A (B20.4.1.1)
in vivo [31]. Daily oral administration of GDC-0980 at a maximum
tolerated dose of 10 mg/kg was efficacious in the HM-7 xenograft
model and resulted in 75% TGI (tumor volume at end of treatment,
control: 882.35 ± 107.27 mm3; GDC-0980: 215.31 ± 21.19 mm3,
P < .001; Figure 1A). Moreover, GDC-0980 was significantly more
efficacious than B20.4.1.1 (B20.4.1.1: 447.55 ± 49.61 mm3, P < .01;
Figure 1. GDC-0980 is efficacious in the HM-7 colorectal cancer
xenograftmodel. (A)Mean tumor volumes fromHM-7 tumor–bearing
mice (n= 8) treated daily and p.o. with MCT vehicle (control) or GDC-
0980 (10 mg/kg) for 7 days. B20.4.1.1 (10 mg/kg) was administered
i.p. on days 1 and 7. Comparisons to control were performed using
Dunnett’s method; comparisons between treatment groups were
performed using unpaired t test assuming unequal variances: **P <
.01, ***P < .001. (B and C) HM-7 tumor–bearing mice (n = 4) were
treatedwith a single oral dose ofGDC-0980 (10mg/kg) and harvested
1 hour post-dose to measure the levels of pAkt (S473) normalized to
tAkt (B) or pS6RP (S235/236) normalized to tS6RP (C). *P<.05, **P<.01
compared tocontrol usingunpaired t test assumingunequal variances.
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Figure 1A). Additionally, GDC-0980 treatment reduced the levels
of PI3K and mTORC1/C2 proximal biomarkers, pAkt and pS6RP,
respectively. Tumor pAkt levels were reduced by 71% (control:
0.028 ± 0.005; GDC-0980: 0.008 ± 0.002, P < .01) and pS6RP levels
were reduced by 55% (control: 0.58 ± 0.15; GDC-0980: 0.26 ± 0.05,
P < .05; Figure 1, B and C ).
To assess the antivascular effects of GDC-0980, ex vivo micro-CT
angiography was used to assess structural changes in the vasculature
of HM-7 tumors with B20.4.1.1 employed as a positive control.
Compared to control, both GDC-0980 and B20.4.1.1 significantly
reduced vascular density relative to control (100 × vascular volume/
tumor volume, control: 5.6 ± 0.4%; GDC-0980: 2.6 ± 0.2%, P <
.001; B20.4.1.1: 3.8 ± 0.5%, P < .01; Figure 2, A and B), where the
GDC-0980 group was also significantly reduced relative to the
B20.4.1.1 group (P < .05). Assessment of the vascular endothelial
marker, MECA-32, by IHC confirmed a significant reduction in
the vascular area fraction (VAF = vascular area/viable tumor area)
for both B20.4.1.1 and GDC-0980 treatments, with B20.4.1.1 also
reduced relative to GDC-0980 (100 × VAF, control: 4.22 ± 0.36%;
B20.4.1.1: 1.79 ± 0.16%, P < .001; GDC-0980: 3.22 ± 0.26%, P <
.05; Figure 2, C and D). Histologically, the presence of small clusters
of MECA-32–positive endothelial cells appears to have increased the
vascular area estimate for the GDC-0980–treated groups since these
vessels were not readily visible in the control or B20.4.1.1 groups
(Figure 2C ). These small MECA-32–positive cell clusters may rep-
resent remnants of collapsed vessels as a result of an antivascular re-
sponse to GDC-0980 and may have been undetected by micro-CT
angiography due to a lack of patency.
To specifically address whether a loss of patency contributed to the
antivascular response by GDC-0980, in vivo multispectral VSI MRI
Figure 2. GDC-0980 reduces vascular density in the HM-7 colorectal cancer xenograft model. (A) Representative 3D renderings of the
micro-CT–derived vascular skeleton (red) overlaid onto the tumor tissue (gray) 24 hours following a single dose of MCT vehicle (control),
B20.4.1.1 (10 mg/kg), or GDC-0980 (10 mg/kg). (B) Micro-CT angiography results for mean vascular volume/tumor volume ± SEM 24 hours
post-treatment (control, n = 9; B20.4.1.1, n = 10; GDC-0980, n = 10). (C) Representative MECA-32 IHC images from the same groups and
(D) the corresponding group estimates for mean vascular fraction (%) = (vascular area/viable tumor area) × 100± SEM. *P< .05, **P< .01,
***P < .001 compared to control using Dunnett’s method.
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[25] was performed on HM-7 tumor xenografts pre-treatment and
post-treatment with 10 mg/kg GDC-0980. Within 24 hours,
GDC-0980 suppressed the growth of viable tumor relative to control
(control: 34 ± 6 mm3; GDC-0980: −7 ± 7 mm3, P < .001;
Figure 3A). Although, GDC-0980 did not produce a significant
change in percent necrosis relative to control after 24 hours of treat-
ment (control: −9.7 ± 1.1%; GDC-0980: −12.7 ± 1.3%, P = .11).
Structurally, the vessel density–related parameter, Q, was significantly
decreased following GDC-0980 treatment compared to the control
(control: −0.013 ± 0.003 ms−1/3; GDC-0980: −0.027 ± 0.005 ms−1/3,
P < .05; Figure 3B). In addition, GDC-0980 treatment resulted in an
increase in mean vessel size (relative to pre-treatment estimates) that
was three-fold greater than the changes observed in the control tumors
(control: 3.1 ± 1.3 μm;GDC-0980: 12.9 ± 3.0 μm, P < .05; Figure 3C).
However, fractional BV changes for GDC-0980 did not differ from
control (Figure 3D), which may be attributed to a combined loss of
vessels and an increase in vessel size. Collectively, the VSI MRI imaging
data suggest that a loss of small functional vessels results in a decrease
in vascular density and an increase in mean vessel size after GDC-
0980 treatment.
GDC-0980 Strongly Alters Vascular Function
To determine functional changes within the vascular structure
after GDC-0980 treatment, multispectral DCE-MRI was employed
to elucidate effects on perfusion/permeability by measuring the vol-
ume transfer constant (K trans), extravascular extracellular space (ve),
and fractional plasma volume (vp) within the viable tumor [23].
GDC-0980 treatment suppressed viable tumor growth of HM-7
tumors by 24 hours (control: 24.1 ± 3.9 mm3; GDC-0980: 10.6 ±
4.3 mm3, P < .05) but not at 4 hours (control: 4.7 ± 3.2 mm3;
GDC-0980: −1.5 ± 3.5 mm3, P = .204; Figure 4, A and B). GDC-
0980 did not produce a significant change in percent necrosis relative
to control at 4 hours (control: −5.5 ± 3.9%; GDC-0980: 0.6 ± 4.8%,
P = .34) nor at 24 hours (control: −9.0 ± 4.1%; GDC-0980: −10.0 ±
2.1%, P = .83). However, 4 hours post-treatment, GDC-0980 re-
duced K trans relative to pre-treatment estimates and relative to the
changes observed in the control group (control: 2.9 ± 7.4%; GDC-
0980: −28.1 ± 3.9%, P < .01; Figure 4, A and C ). This reduction per-
sisted for 24 hours (control: 4.1 ± 6.6%; GDC-0980: −36.0 ± 6.1%,
P < .001) post-treatment indicating decreased delivery of the contrast
agent due to effects on blood flow and/or vascular permeability. Addi-
tionally, GDC-0980 treatment increased ve at 4 (control: −13.8 ±
4.9%; GDC-0980: 21.5 ± 6.4%, P < .001) and 24 hours (control:
−11.8 ± 4.6%;GDC-0980: 28.2 ± 11%, P < .01, Figure 4D) relative to
changes observed in the control group. However, differences between
control and treated groups were not observed in vp at either time point
(Figure 4E ).
Since the DCE-MRI parameter K trans is sensitive to both blood
flow and permeability, DCE-U/S imaging with an intravascular con-
trast agent was used to assess the effects of GDC-0980 on blood flow
in HM-7 tumor–bearing mice. GDC-0980 significantly reduced
blood flow within the enhancing region of the tumor relative to
Figure 3. Inhibition of PI3K andmTORC1/C2 results in a significant loss of functional vessels in the HM-7 colorectal cancer xenograft model.
(A–D) VSI MRI–derived raw change in (A) viable tumor volume, (B) Q, which is proportional to vessel density, (C) VSI, and (D) fractional BV
24 hours post-treatment with 10 mg/kg GDC-0980 or MCT (control); mean ± SEM, n= 9/group. *P< .05, ***P< .001 compared to control
using unpaired t test assuming unequal variances. #P < .05, ##P < .01, ###P < .001 versus pre-treatment by paired t test.
700 Antivascular Effects of PI3K Inhibitors Sampath et al. Neoplasia Vol. 15, No. 7, 2013
pre-treatment values and to changes observed in the control group
(control: −11.5 ± 7.5%; GDC-0980: −69.2 ± 4.9%, P < .001; Fig-
ure 5, A and B), consistent with an increase in vasoconstriction
due to inhibition of VEGF activity, a known vasodilator [43]. Fur-
thermore, GDC-0980 produced a significant decrease in the en-
hancement factor (E f; control: −7.8 ± 3.1%; GDC-0980: −53.1 ±
5.7%, P < .001; Figure 5C ), which is consistent with a reduction
in vascular density.
Inhibition of PI3K Directly Reduces Endothelial Cell
Migration, Sprout Formation, and Viability
Since treatment with GDC-0980 resulted in a robust antiangio-
genic response, the question arises whether the effects on vascular
structure and functions were due to inhibition of PI3K, mTOR,
or both. To test this hypothesis, studies were performed with a small
molecule inhibitor that selectively targets class I PI3K (GNE-490)
and has similar biochemical and cellular potencies to GDC-0980
Figure 4. Inhibition of PI3K and mTORC1/C2 affects vascular function in HM-7 xenograft model as assessed by DCE-MRI. (A) Repre-
sentative false-colorized DCE-MRI K trans maps for the viable tumor regions pre-treatment as well as 4 and 24 hours post-treatment with
MCT vehicle control (n = 11) or 7.5 mg/kg GDC-0980 (n = 9) overlaid onto the corresponding proton density image. (B–E) Multispectral
DCE-MRI–derived (B) change in viable tumor volume, (C) percent change in K trans, (D) percent change in ve, and (E) percent change in vp
for tumor-bearing mice described in A (mean ± SEM). *P < .05, **P < .01, ***P < .001 versus control by unpaired t test assuming
unequal variances; #P < .05, ##P < .01, ###P < .001 versus pre-treatment by paired t test.
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but does not target mTORC1/C2 [26]. In addition, GNE-490 has
similar drug exposures in immunocompromised mice to GDC-0980
that is ideal for accurately comparing the pharmacodynamic re-
sponses and efficacy of both drugs in vivo [28,30].
Initially, the direct effects of GNE-490 and GDC-0980 on endo-
thelial cells were compared in vitro using HUVECs as a model. Com-
pared to GDC-0980, GNE-490 suppressed the phosphorylation of
PI3K pathway biomarkers (pAkt, pS6RP, and p4EBP) and decreased
phosphorylation of eNOS to similar degrees (Figure 6A). In addition,
GNE-490 and GDC-0980 significantly inhibited HUVEC migra-
tion by 80% and 75%, respectively, relative to control treatment af-
ter growth factor stimulation (mean cell migration index, control:
2.42 ± 0.11; GNE-490: 0.48 ± 0.06, P < .001; GDC-0980: 0.6 ±
0.06, P < .001; Figure 6B). To evaluate the functional consequences
of the migration defect, we measured the effects of GNE-490 and
GDC-0980 on endothelial sprout formation. Both GNE-490 and
GDC-0980 significantly suppressed formation of elongated sprouts
by 59% and 48%, respectively (mean total vessel outgrowth, control:
2175.45 ± 48.92; GNE-490: 901.14 ± 60.95, P < .001; GDC-0980:
1121.97 ± 56.73, P < .001; bevacizumab: 894.1 ± 90.14, P < .001;
Figure 6, C and D). Moreover, the inhibitory effects on sprouting
were similar between anti-human VEGF-A (bevacizumab), GNE-
490, and GDC-0980 (Figure 6, C and D). Consistent with a less
motile phenotype, morphologically, the sprouts that remained after
GNE-490 and GDC-0980 treatment contained blunted tips with
few filopodia when compared to untreated cells (Figure 6C , inset).
The inhibition of endothelial cell sprouting by treatment with either
GNE-490 or GDC-0980 may, in part, be due to increased apoptotic
cell death (mean apoptotic index, control: 1.25 ± 0.19; GNE-490:
3.91 ± 0.7, P < .01; GDC-0980: 3.75 ± 0.49, P < .01; Figure 6E ).
Selective Inhibition of PI3K Is Sufficient for Reducing
Vascular Density
Given that PI3K inhibition by GNE-490 was sufficient to directly
reduce endothelial cell migration, survival, and sprouting in vitro,
GNE-490 effects on vascular structure were evaluated in vivo.
Figure 5. Inhibition of PI3K and mTORC1/C2 affects vascular function in the HM-7 xenograft model as assessed by DCE-U/S. (A) Rep-
resentative false-colorized DCE-U/S blood flow maps overlaid onto their anatomic images pre-treatment or 24 hours post-treatment with
MCT vehicle (control) or 7.5 mg/kg GDC-0980 (n = 6/group). (B and C) Percent change in DCE-U/S–derived (B) blood flow in the enhanc-
ing tumor regions and (C) enhancement factor for tumor-bearing mice described in A (mean ± SEM). ***P < .001 versus control by
unpaired t test assuming unequal variances; #P < .05, ###P < .001 versus pre-treatment by paired t test.
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Vascular density assessed by micro-CT angiography of HM-7 tumors
was reduced relative to control following treatment with GNE-490,
which was comparable to GDC-0980 and B20.4.1.1 (control: 4.8 ±
0.32%; GNE-490: 2.5 ± 0.2%; GDC-0980: 2.5 ± 0.28%,
B20.4.1.1: 2.6 ± 0.23%; P < .001 vs control for all treatments; Fig-
ure 7, A and B). In addition, GNE-490 reduced vascular density in
another anti–VEGF-A sensitive xenograft model (NCI-PC3 prostate
cancer) relative to control that was comparable to reductions produced
Figure 6. Inhibition of PI3K reduces endothelial cell migration, sprout formation, and viability in vitro. (A) HUVECs were stimulated with EGM-2
growth factormedia for 1 hour in the presence ofDMSOvehicle (control), 0.40μMGNE-490, or 0.40μMGDC-0980 before immunoblot analysis
for PI3K pathwaymarkers and eNOS as shown. (B) HUVECmigration was induced with EGM-2 growth factor media in the presence of DMSO
(control), 0.4 μMGNE-490, or 0.4 μMGDC-0980 for 72 hours and quantified as mean ± SEM. (C) Representative images of established endo-
thelial sprouts after treatmentwith 20 μg/ml control antibody (anti-ragweed), 20 μg/ml bevacizumab, 0.40 μMGNE-490, and 0.40μMGDC-0980
for 4 days. Cells were imaged using Molecular Devices ImageXpress Micro automated microscope with a 4× S Fluor objective and (D) quan-
tified for total vessel outgrowth/bead (mean ± SEM). (C, bottom row) Higher resolution representative images (10×) of endothelial sprout tips.
(E) Endothelial cell apoptosiswasmeasured by a nuclear ELISA assay after treatmentwithDMSOvehicle (control), 0.40μMGNE-490, or 0.40 μM
GDC-0980 for 48 hours and quantified as mean optical density ± SEM. **P< .01, ***P < .001 compared to control using Dunnett’s method.
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byGDC-0980 andB20.4.1.1 (control: 0.95 ± 0.12%; B20.4.1.1: 0.60 ±
0.06%; GDC-490: 0.67 ± 0.069%; GDC-0980: 0.67 ± 0.067%; P <
.05 vs control for all treatments; Figure 7, C and D). The antivascular
response was also confirmed in the HM-7 model after daily dosing of
drugs for 7 days in which GDC-0980, GNE-490, and B20.4.1.1 exhib-
ited a similar reduction in MECA-32–positive vessels (100 × VAF, con-
trol: 1.96 ± 0.12%; GDC-0980: 1.11 ± 0.09%, P < .001; GNE-490:
0.97 ± 0.16%, P < .001; B20.4.1.1: 1.28 ± 0.16%, P < .01; Figure 7,
E and F ). Moreover, the small MECA-32–positive vessels that were
present 24 hours after a single dose of GDC-0980 (Figure 2C ) were
not detectable after continuous daily treatment (Figure 7E). The anti-
vascular effects of GNE-490 and GDC-0980 were not due to a suppres-
sion of HM-7 tumor–derived VEGF-A secretion since GDC-0980 and
GNE-490 did not significantly reduce the expression of human VEGF-
A165 or VEGF-A121 isoforms relative to control levels (Figure W1).
The pharmacodynamic effects of GNE-490 was confirmed to be
on-target based on a 73% reduction of pAkt (control: 0.044 ± 0.003;
GNE-490: 0.012 ± 0.002, P < .001) and a 61% reduction in pS6RP
(control: 0.69 ± 0.08; GNE-490: 0.27 ± 0.04, P < .001) in HM-7
tumors (Figure 8, A and B). Relative to control treatment, GNE-490
Figure 7. Inhibition of PI3K is sufficient for reducing vascular density in HM-7 and NCI-PC3 xenograft models. (A) HM-7 xenograft model:
micro-CT angiography results of mean vascular volume/tumor volume ± SEM 24 hours following a single dose of MCT vehicle (control),
B20.4.1.1 (10 mg/kg), GNE-490 (30 mg/kg), or GDC-0980 (10 mg/kg) (HM-7 xenograft model). (B) Representative 3D renderings of the
micro-CT–derived vascular skeleton (red) overlaid onto HM-7 tumor tissue (gray) from mice described in A. (C) NCI-PC3 xenograft model:
micro-CT angiography results of mean vascular volume/tumor volume ± SEM 48 hours following a single dose of MCT vehicle (control),
B20.4.1.1 (10 mg/kg), GNE-490 (30 mg/kg), or GDC-0980 (10 mg/kg). (D) Representative 3D renderings of the micro-CT–derived vascular
skeleton (red) overlaid onto NCI-PC3 tumor tissue (gray) from mice described in C. (E) Representative IHC images of MECA-32–positive
vessels contained in HM-7 tumors after 7 days of daily treatment with MCT vehicle (control), 10 mg/kg B20.4.1.1, 30 mg/kg GNE-490, or
10 mg/kg GDC-0980 and (F) the corresponding estimates for mean vascular fraction (%) = (vascular area/viable tumor area) × 100 ± SEM,
n = 10/group. Comparisons to control were performed using Dunnett’s method; *P < .05, **P < .01, ***P < .001.
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also reduced pAkt levels by 74% (control: 0.034 ± 0.002; GNE-490:
0.009 ± 0.001, P < .001) and reduced pS6RP levels by 69% (control:
0.55 ± 0.01; GNE-490: 0.17 ± 0.02, P < .001) in NCI-PC3 tumors
(Figure 8, C and D). Given that pS6RP is a proximal biomarker for
mTOR inhibition, a significant reduction in pS6RP levels was also
observed with GDC-0980 when compared to GNE-490 in both
HM-7 (GDC-0980: 0.14 ± 0.03, P < .05) and NCI-PC3 (GDC-
0980: 0.11 ± 0.01, P < .05) xenograft models (Figure 8, B and D).
However, the significant reduction of pAkt and pS6RP by GNE-490 in
both xenograft models demonstrates that robust PI3K pathway suppres-
sion can be achieved at the level of PI3K inhibition. The latter findings
correlated well with the antitumor effects of GNE-490 in which drug
Figure 8. GNE-490 reduces pAkt, pS6RP, and tumor growth in HM-7 colorectal cancer and NCI-PC3 prostate cancer xenograft models.
(A and B) HM-7 tumor–bearing mice (n= 3) were treated with a single oral dose of GDC-0980 (10 mg/kg) or GNE-490 (30 mg/kg) or i.p. dose
of B20.4.1.1 (10 mg/kg) and harvested 1 hour post-dose to measure the levels of pAkt (S473) normalized to tAkt (A) or pS6RP (S235/236) nor-
malized to tS6RP (B) usingMeso Scale Discovery assays (mean ± SEM). (C and D) NCI-PC3 tumor–bearing mice (n= 4) were treated with a
single dose ofMCT vehicle (control), GDC-0980 (10mg/kg), or GNE-490 (30mg/kg), and tumors were harvested 1 hour post-dose tomeasure
the levels of pAkt (S473) normalized to tAkt (C) or pS6RP (S235/236) normalized to tS6RP (D). (E and F) Mean tumor volumes from HM-7 (E) and
NCI-PC3 (F) tumor–bearing mice treated daily and p.o. with MCT vehicle (control), GDC-0980 (10 mg/kg), or GNE-490 (30 mg/kg) for 7 days.
B20.4.1.1 (10mg/kg) was administered i.p. on days 1 and 7. Comparisons to control were performed using Dunnett’s method; comparisons
between treatment groups were performed using unpaired t test assuming unequal variances: *P < .05, **P < .01, ***P < .001.
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treatment inhibited tumor growth by 78% in the HM-7 model (con-
trol: 1129.86 ± 135.57 mm3; GNE-490: 246.71 ± 25.26 mm3, P <
.001; GDC-0980: 294.85 ± 30.84 mm3, P < .001; B20.4.1.1:
525.82 ± 68.50 mm3, P < .001) and 68% in the NCI-PC3 model
(control: 479.74 ± 31.15 mm3; GNE-490: 153.73 ± 11.22 mm3, P <
.001; GDC-0980: 165.37 ± 25.01 mm3, P < .001; B20.4.1.1: 336.62 ±
27.08 mm3, P < .001; Figure 8, E and F). GDC-980 inhibited HM-7
tumor growth by 74% and NCI-PC3 tumor growth by 66% and,
therefore, was as efficacious as GNE-490 in both xenograft models
(Figure 8, E and F ). Moreover, GNE-490 was more efficacious than
B20.4.1.1 in both the HM-7 (P < .05) and NCI-PC3 (P < .001) xeno-
graft models, suggesting that selective inhibition of PI3K is sufficient to
induce a combined antitumorigenic and antivascular response that trans-
lates into greater TGI when compared to drugs that target the tumor
vasculature alone such as anti–VEGF-A (Figure 8, E and F).
To confirm that inhibition of PI3K was sufficient to reduce vas-
cular density, selective mTOR inhibitors, rapamycin (mTORC1) or
GNE-861 (mTORC1/C2), were combined with GNE-490 and the
effects on vascular structure were evaluated in HM-7 xenografts by
micro-CT angiography. Both rapamycin (control: 5.5 ± 0.36%;
GNE-490: 3.2 ± 0.24%, P < .001; rapamycin: 5.1 ± 0.48%, P =
.7; GDC-490 + rapamycin: 3.0 ± 0.19%, P < .001; Figure 9A)
and GNE-861 (control: 5.7 ± 0.5%; GNE-490: 3.8 ± 0.2%, P <
.01; GNE-861: 5.0 ± 0.6%, P = .55; GNE-490 + GNE-861: 3.5 ±
0.3%, P < .01; Figure 9B) were included in separate four-arm com-
bination studies with GNE-490. Neither rapamycin nor GNE-861
treatment alone reduced vascular density relative to control. Moreover,
the addition of rapamycin or GNE-861 to GNE-490 treatment did
not reduce vascular density when compared to GNE-490 alone. Ad-
ditionally, when compared with GNE-490 treatment alone, rapa-
mycin did not significantly enhance the efficacy of GNE-490 when
both drugs were combined in the HM-7 xenograft model (GNE-490:
218.97 ± 18.59 mm3; GNE-490 + rapamycin: 161.83 ± 16.75 mm3,
P = .45; Figure 9C ). We confirmed that, GNE-490, rapamycin and
Figure 9. Combination of mTOR inhibitors with GNE-490 does not further reduce vascular density compared to GNE-490 alone in HM-7
xenograft model. (A and B) Micro-CT angiography results of mean vascular volume/tumor volume± SEM 24 hours following a single dose
ofMCT vehicle (control), 30mg/kg GNE-490, 6mg/kg rapamycin (A), 30mg/kg GNE-490+ 6mg/kg rapamycin (A), 100mg/kg GNE-861 (B),
or 30 mg/kg GNE-490 + 100 mg/kg GNE-861 (B) (n= 8–10/group). (C) Mean tumor volumes for HM-7 tumor–bearing mice (n= 8) treated
daily and p.o. with MCT vehicle (control), GNE-490, rapamycin, or the combination of GNE-490 and rapamycin for 7 days at the doses
indicated. (D) The ratio of pS6RP (S235/236) to tS6RP in tumors from HM-7 tumor–bearing mice (n= 4) was treated with a single oral dose
of GNE-490 (30 mg/kg), rapamycin (6 mg/kg), or the combination of GNE-490 and rapamycin (mean ± SEM). Comparisons to control were
performed using Dunnett’s method; comparisons between treatment groups were performed using unpaired t test assuming unequal
variances: *P < .05, **P < .01, ***P < .001.
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the combination of GNE-490 and rapamycin were indeed pharmaco-
logically active as significant reductions in pS6RP tumor levels of
76%, 75%, and 71%, respectively, were observed when compared to
control levels (control: 0.89 ± 0.09; GNE-490: 0.21 ± 0.02, P < .001;
rapamycin: 0.22 ± 0.02, P < .001; GNE-490 + rapamycin: 0.26 ±
0.01, P < .001; Figure 9D). Collectively, our evaluation of GNE-490
and mTOR-specific inhibitors suggests that selective inhibition of
PI3K is sufficient to produce a robust antivascular response in vivo.
Selective Inhibition of PI3K Is Sufficient for
Reducing Vascular Function
Selective inhibition of PI3K by GNE-490 on vascular function
was assessed by DCE-MRI and DCE-U/S in the HM-7 xenograft
tumor model. Twenty-four hours following treatment with GNE-
490 or GDC-0980, viable tumor growth was reduced (control:
43.6 ± 4.9 mm3; GNE-490: 7.2 ± 2.9 mm3; GDC-0980: −5.3 ±
2.2 mm3; P < 0.001 for both treatment groups; Figure 10, A and
B). Both GNE-490 (4.0 ± 2.5%, P < 0.01) and GDC-0980 (1.5 ±
2.9%, P < .05) groups exhibited an increase in percent necrosis relative
to control (−8.6 ± 2.1%) but not relative to pre-treatment values. K trans
was reduced within the viable tumor by GNE-490 and GDC-0980
relative to pre-treatment values and the changes observed under control
treatment (control: −1.4 ± 4.9%; GNE-490: −21.5 ± 7.0%, P < .05;
GDC-0980: −28.7 ± 5.4%, P < .01; Figure 10, A and C). GDC-0980
induced a reduction in vp when compared to changes observed in the
control-treated animals, whereas GNE-490 did not produce a signifi-
cant response relative to control (control: −5.9 ± 8.6%; GNE-490:
−21.1 ± 9.4%, P = .321; GDC-0980: −38.7 ± 5.7%, P < .01;
Figure 10D). Relative to control, GDC-0980 produced a significant
increase in ve, while GNE-490 did not (control: −0.59 ± 5.2%;
GNE-490: 14.9 ± 9.9%, P = .2; GDC-0980: 25.0 ± 5.0%; P < .05;
Figure 10E ). Although GNE-490 did not alter vp or ve relative to
control, there were no significant differences between the GDC-0980
and GNE-490 treatment groups for any of the DCE-MRI parameters
that were measured.
DCE-U/S detected a trend toward decreased blood flow in the
enhancing tumor regions following treatment with GNE-490 or
GDC-0980 that did not differ significantly from control (control: −1.4 ±
10.1%; GNE-490: −23.7 ± 6.0%, P = .123; GDC-0980: −20.7 ±
7.3%, P = .18; Figure 11, A and B). However, the percent change in
E f was significantly reduced by both GNE-490 and GDC-0980 rela-
tive to changes measured in the control group (control: 2.4 ± 2.3%;
GNE-490: −13.8 ± 2.8, P < .05; GDC-0980: −16.0 ± 6.3, P < .05;
Figure 11, A and C ). There were no significant differences between
GNE-490 and GDC-0980 groups for percent change in blood flow
or E f (Figure 11, B and C ).
The effects of GNE-490 versus GDC-0980 on vascular endothelial
cell function were further evaluated by FMD and NTG responses in
non–tumor-bearing mice. FMD assesses the ability of endothelial
cells to respond to a hypoxic challenge that leads to increased eNOS
production of NO that induces vasodilation. In the NTG experiment,
NTG directly stimulates vascular smooth muscle cells to induce vaso-
dilation and bypasses any effects on endothelial cell signaling. For
FMD experiments, ultrasound imaging was used to monitor FA
diameter prior and after a transient occlusion of blood flow to the right
leg by a rubber band cuff. Eight minutes after the FMD experiment was
Figure 10. Inhibition of PI3K affects vascular function in HM-7 xenograft model as assessed by DCE-MRI. (A) Representative false-
colorized DCE-MRI K trans maps for the viable tumor regions pre-treatment as well as 24 hours post-treatment with MCT vehicle (control,
n = 14), GNE-490 (30 mg/kg, n = 11), or GDC-0980 (10 mg/kg, n = 13) overlaid onto the corresponding proton density image (HM-7
xenograft model). The percent change from baseline is noted. (B–E) Multispectral DCE-MRI–derived (B) change in viable tumor volume,
(C) percent change in K trans, (D) percent change in vp, and (E) percent change in ve for the mice described in A (mean ± SEM). *P < .05,
**P< .01, ***P< .001 compared to control using Dunnett’smethod; #P< .05, ##P< .01, ###P< .001 versus pre-treatment by paired t test.
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completed, an NTG-mediated dilation/endothelial cell–independent
experiment was performed on the opposite leg. GDC-0980 strongly
suppressed the FMD response, whereas GNE-490 exhibited a modest
trend (Figure 11, D and E). The differences between GNE-490 and
GDC-0980 FMD responses were insignificant and neither drug was
able to suppress the ability of NTG to directly stimulate vascular smooth
muscle cells to promote vasodilation (Figure 11, F and G). The FMD
study demonstrates that GDC-0980 and, possibly, GNE-490, to a
Figure 11. GNE-490 is sufficient for reducing tumor perfusion assessed by DCE-U/S, whereas GDC-0980 suppresses hypoxia-induced FMD
in normal vasculature. DCE-U/S: A–C. (A) Representative false-colorized DCE-U/S blood flowmaps overlaid onto their anatomic images pre-
treatment or 24 hours post-treatment withMCT vehicle (control, n=8), GNE-490 (30mg/kg, n=7), or GDC-0980 (10mg/kg, n=8). (B and C)
Mean percent change ± SEM in DCE-U/S–derived (B) blood flow in the enhancing tumor regions and (C) enhancement factor for the mice
described in A. FMD and NTG experiments: D–G. (D) Mean diameter of the FA before and following a transient (4-minute) occlusion of blood
flow to the right leg 4 hours post-treatment with 30 mg/kg GNE-490, 10 mg/kg GDC-0980, or MCT (control) ± SEM (n = 9/group). (E) Area
under the curve for the plots in D (mean ± SEM). (F) Mean diameter of the FA of the left leg before and following NTG-mediated dilation
4 hours post-treatment with 30 mg/kg GNE-490, 10 mg/kg GDC-0980, or MCT (control) ± SEM (n= 9/group). (G) Area under the curve for the
plots in E (mean ± SEM). *P < .05 compared to control using Dunnett’s method; #P < .05, ##P < .01 versus pre-treatment by paired t test.
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lesser extent, were able to specifically suppress eNOS production of
NO in endothelial cells.
Discussion
In this study, selective class I PI3K, dual PI3K/mTOR, and mTOR
small molecule inhibitors were evaluated using multimodal imaging
techniques to elucidate the overall contributions of PI3K versus PI3K
and mTOR activity on tumor vascular structure and function in
colorectal and prostate cancer xenograft models that are sensitive to
anti–VEGF-A treatment. Initially, these studies focused on the dual
PI3K/mTOR inhibitor, GDC-0980, to determine its effects on vas-
cular structure and function when both PI3K and mTOR are simul-
taneously blocked in the HM-7 colorectal cancer xenograft model.
On the basis of ex vivo micro-CT angiography, a single dose of
GDC-0980 produced a strong antivascular response comparable to
anti–VEGF-A monotherapy. In addition, this robust antivascular
effect was confirmed by treatment of HM-7 xenografts with daily
(7 days) doses of GDC-0980 and resulted in a decrease in MECA-
32–positive endothelial cells that was comparable to anti–VEGF-A
monotherapy. GDC-0980 treatment also induced a robust suppres-
sion of PI3K proximal and distal pathway markers, such as pAkt and
pS6RP, respectively, in tumors. This tumor cell response did not re-
sult in acute tumor cell killing since multispectral MRI did not detect
a robust increase in percent necrosis after 24 hours of treatment.
However, compared to anti–VEGF-A, GDC-0980 treatment re-
sulted in greater TGI likely due to both PI3K pathway inhibition
in tumor cells and a strong antivascular effect on the endothelium.
The compromised vascular structure induced by GDC-0980 corre-
sponded to diminished function in vivo since a strong decrease in the
DCE-MRI parameter, K trans, was observed after a single dose, indi-
cating a rapid alteration of vascular permeability and/or blood flow in
the viable tumor region. In addition, DCE-U/S and VSI MRI con-
firmed a reduction in functional perfusion and vessel density, respec-
tively, after GDC-0980 treatment. Thus, these initial studies led to
the conclusion that inhibition of both PI3K and mTOR by GDC-
0980 results in potent antivascular and antitumorigenic effects that
translate into greater efficacy when compared to anti–VEGF-A treat-
ment. The effects on vascular function by GDC-0980 corroborates
the work of Schnell et al. where treatment of the BN472 mammary
carcinoma allograft model with BEZ-235, a dual PI3K/mTOR in-
hibitor, inhibited microvessel permeability, reduced tumor interstitial
pressure, and decreased K trans [19]. However, the study of Schnell
et al. did not evaluate the effects of the dual PI3K/mTOR inhibition
on vessel structure, whereas our evaluation of GDC-0980 by micro-
CT angiography and VSI MRI identified a strong structural anti-
vascular response that is produced by this class of drugs.
Initially, evaluating the antivascular effects of GDC-0980 estab-
lished a benchmark that permitted further interrogation of PI3K
alone using selective inhibitors such as GNE-490 that has compa-
rable potency against PI3K and drug exposures in mice to GDC-0980
[28]. The potent antivascular effects of GNE-490 were confirmed in
the HM-7 and NCI-PC3 xenograft models by micro-CT angiog-
raphy and resulted in a significant reduction in vascular density that
was similar to GDC-0980. The impact of GNE-490 on an array of
functional vascular end points did not differ significantly from re-
sponses observed with GDC-0980, suggesting that PI3K inhibition
was sufficient to inhibit tumor vascular function. Moreover, the combi-
nation of GNE-490 with mTOR inhibitors, rapamycin or GNE-861,
did not further reduce vascular density nor enhance the efficacy of
GNE-490. The comparable antivascular activity of GNE-490 and
GDC-0980 in vivo is likely due to a direct effect on vascular endo-
thelial cells since both drugs suppressed PI3K pathway markers lead-
ing to reduced endothelial cell migration and sprouting and increased
cell death in vitro. Collectively, these data demonstrate that selective
PI3K inhibition is sufficient to induce potent antivascular responses
that combine with strong antitumorigenic activity to maximize
efficacy in vivo.
There are some differences in the functional imaging results that
may be due to technical limitations. Although there were no signi-
ficant differences between DCE-MRI, DCE-U/S, and FMD re-
sponses for GNE-490 and GDC-0980 treatment, GDC-0980
produced significant responses in five end points (K trans, vp, ve, E f,
and FMD AUC), whereas GNE-490 generated significant responses
in two end points (K trans and E f). This may be due to limitations in
precisely matching exposures throughout the treatment window, where
functional end points may be very sensitive to drug levels at the time of
the imaging exam. Another question arises from the differences
between the two DCE-MRI studies, namely, lack of a GDC-0980 vp
response in the first study and a strong GDC-0980 vp response in the
second. This may be due to the use of an optimized DCE-MRI proto-
col in the second study that provided an improved temporal resolution
yielding a more accurate estimate of vp.
Inactivation of the p110α isoform of class I PI3K by genetic knock-
down or expression of a kinase dead mutant (D933A) in immuno-
competent mice supports the strong antivascular effects observed
when PI3K is inhibited [18]. Compared to p110β and δ, p110α ac-
tivity is essential for vascular development as evidenced by severe de-
fects in angiogenic sprouting and remodeling, leading to embryonic
lethality at E12.5 [18]. Moreover, treatment of immortalized cardiac
endothelial cells in vitro with a p110α selective inhibitor, PI-103, re-
sulted in VEGF-A–dependent decreased tube formation [18]. Thus,
p110α may be sufficient to regulate VEGF-A developmental angio-
genesis and, in part, supports our antivascular observations in tumors
treated with GNE-490.
Modulation of the tumor vasculature by the selective class I PI3K
inhibitor, GDC-0941, has recently been shown to result in increased
delivery of chemotherapeutic drugs through a vasculature normaliza-
tion mechanism [44]. In these studies, oral administration of GDC-
0941 in SQ20B human head and neck tumor xenografts resulted in
increased perfusion, as measured by 3D power Doppler ultrasound
[44]. Structurally, treatment with GDC-0941 produced vascular re-
modeling or normalization characterized by vessels that were less tor-
tuous and longer in length compared to control animals [44]. This
induction of vascular normalization led to increased delivery of doxo-
rubicin and increased efficacy when combined with GDC-0941.
While the results of Qayum et al. [44] differ from our findings with
regard to reduced vascular function by GNE-490, it should be noted
that doses of GDC-0941 were nonefficacious in the SQ20B xeno-
graft model. Therefore, differential vascular responses (normalization
vs antivascular) may be observed with PI3K inhibitors depending on
the doses (nonefficacious vs efficacious) administered in these pre-
clinical xenograft models.
Advancement of selective PI3K inhibitors in clinical development
can be guided by the ability to rapidly assess their pharmacodynamic
activity directly in tumors. In vivo imaging techniques offer an attractive
alternative to serial biopsies because they are noninvasive and provide
whole-tumor coverage making them less prone to sampling errors.
While FDG-PET has proven successful at detecting rapid alterations
Neoplasia Vol. 15, No. 7, 2013 Antivascular Effects of PI3K Inhibitors Sampath et al. 709
in tumor glucose metabolism following therapy [45], the observed hy-
perglycemia that has been noted with PI3K inhibitors confounds inter-
pretation of the imaging data [39]. Thus, an alternative approach to
assess the pharmacodynamic activity of PI3K or dual PI3K/mTOR
inhibitors, independent of tumor genotypes, involves imaging drug
effects on tumor vasculature. This study focused on an array of
preclinical imaging techniques that were successfully employed to eval-
uate the effects of PI3K and dual PI3K/mTOR inhibitors on tumor
vascular structure and function, the majority of which can be used in
clinical development (VSI MRI, DCE-MRI, and DCE-U/S)
[35,46,47]. DCE-MRI has been widely employed as a pharmacody-
namic end point for antiangiogenic agents and a number of clinical
DCE-MRI studies have been performed to evaluate antiangiogenic
and antivascular agents [35]. In this study, PI3K and dual PI3K/
mTOR inhibitors demonstrated a robust DCE-MRI response charac-
terized by a strong decrease in K trans attributed to changes in blood
flow and/or permeability. It is also noteworthy that these inhibitors
generated antivascular imaging responses that were comparable to
antiangiogenic drugs, such as antibodies to VEGF-A [22,25]. On the
basis of DCE-MRI’s clinical success in monitoring antiangiogenic
agents and the data presented here, DCE-MRI has strong potential
to provide a robust and quantitative means to monitor the pharmaco-
dynamic activity of PI3K inhibitors for testing in cancer patients
and, accordingly, has been included as an end point in the clinical
development of GDC-0980 [48].
In conclusion, PI3K inhibition is sufficient to generate physiolog-
ical and structural changes, characteristic of a robust antivascular re-
sponse. In addition, quantitative microvascular imaging techniques
can be employed to effectively monitor the antivascular responses in-
duced by PI3K and dual PI3K/mTOR inhibitors in vivo, thereby
providing powerful tools to assess the pharmacodynamic activity of
these drugs in patients.
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Figure W1. Tumor VEGF-A levels are not reduced after treatment with class I PI3K selective (GNE-490) or dual PI3K/mTOR (GDC-0980)
inhibitors in vivo. HM-7 tumor–bearing mice (n= 4/group) were treated with a single oral dose of vehicle, GNE-490 (30 mg/kg), or GDC-0980
(10mg/kg). Tumors fromeach groupwere harvested 1, 4, 8, and 24 hours post-dose and analyzed for expression of VEGF-A isoforms 121 and
165 by ELISA as described in Materials and Methods section.
